0001209191-23-004345.txt : 20230123 0001209191-23-004345.hdr.sgml : 20230123 20230123082705 ACCESSION NUMBER: 0001209191-23-004345 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230118 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNeill Jonathan CENTRAL INDEX KEY: 0001824673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 23542592 MAIL ADDRESS: STREET 1: C/O DYNE THERAPEUTICS, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-18 0 0001818794 Dyne Therapeutics, Inc. DYN 0001824673 McNeill Jonathan C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 0 1 0 0 See Remarks Common Stock 2023-01-18 4 M 0 10000 0.73 A 77600 D Common Stock 2023-01-18 4 S 0 10000 14.03 D 67600 D Stock Option (right to buy) 0.73 2023-01-18 4 M 0 10000 0.00 D 2029-02-25 Common Stock 10000 68528 D This is an inadvertent late filing due to an administrative error. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Senior Vice President of Business Development /s/ Richard Scalzo, Attorney-in-Fact 2023-01-23